HIV/TB合并感染儿童使用利福布汀联合洛匹那韦/利托那韦方案的安全性与有效性
该回顾性队列分析了尼日利亚48名需接受PI为基础抗病毒治疗的HIV/TB合并感染儿童,使用含利福布汀的抗结核方案。利福布汀治疗期间不良事件发生率低于基线,仅1例(2%)出现3级中性粒细胞减少,提示在临床和实验室监测下利福布汀是安全有效的选择。
要点
- 利福布汀联合洛匹那韦/利托那韦在HIV/TB合并感染儿童中总体安全,严重中性粒细胞减少罕见。
- 治疗期间不良事件发生率低于基线,但中性粒细胞计数较基线下降,需监测。
核心结论
- 在临床和实验室监测下,利福布汀是接受PI为基础抗病毒治疗的HIV/TB合并感染儿童的安全抗结核选择。
- 与唯一另一项儿童研究不同,本队列中严重中性粒细胞减少罕见。
- 该队列结局提示利福布汀有效,是需要PI为基础抗病毒治疗儿童的新选择。
研究设计与样本
- 回顾性分析2009年至2015年尼日利亚Harvard/APIN项目中48名接受含利福布汀抗结核治疗联合洛匹那韦/利托那韦为基础抗病毒治疗的HIV/TB合并感染儿童。
- 基线中位(IQR)年龄1.7(0.9-5.0)岁,女性占50%,基线中位(IQR)CD4+细胞百分比15%(9%-25%),52%有抗病毒治疗经验。
主要发现
- 不良事件(1-4级)在基线时发生率27%,利福布汀治疗期间为15%(P = 0.006)。
- 利福布汀治疗期间绝对中性粒细胞计数中位数1762 cells/mm3,低于基线的2976 cells/mm3。
- 利福布汀治疗期间仅发生1例(2%)3级中性粒细胞减少。
临床怎么用
- 对于需要PI为基础抗病毒治疗的HIV/TB合并感染儿童,可考虑使用利福布汀作为抗结核治疗选项,但需进行临床和实验室监测。
- 监测应包括中性粒细胞计数等实验室指标,以及时发现血液学毒性。
局限性
- 回顾性研究设计,样本量较小(48例),来自单一项目。
- 缺乏对照组,无法直接比较利福布汀与其他方案的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: TB is the leading cause of death among HIV-infected children, yet treatment options for those who require PI-based ART are suboptimal. Rifabutin is the preferred rifamycin for adults on PI-based ART; only one study has evaluated its use among children on PIs and two of six children developed treatment-limiting neutropenia. METHODS: Since 2009, rifabutin has been available for HIV/TB-coinfected children requiring PI-based ART in the Harvard/APIN programme in Nigeria. We retrospectively analysed laboratory and clinical toxicities at baseline and during rifabutin therapy, and examined HIV/TB outcomes. RESULTS: Between 2009 and 2015, 48 children received rifabutin-containing TB therapy with PI (lopinavir/ritonavir)-based ART: 50% were female with a median (IQR) baseline age of 1.7 (0.9-5.0) years and a median (IQR) CD4+ cell percentage of 15% (9%-25%); 52% were ART experienced. Eighty-five percent completed the 6 month rifabutin course with resolution of TB symptoms and 79% were retained in care at 12 months. Adverse events (grade 1-4) were more common at baseline (27%) than during rifabutin treatment (15%) (P = 0.006). Absolute neutrophil count was lower during rifabutin compared with baseline (median = 1762 versus 2976 cells/mm3, respectively), but only one instance (2%) of grade 3 neutropenia occurred during rifabutin treatment. CONCLUSIONS: With clinical and laboratory monitoring, our data suggest that rifabutin is a safe option for TB therapy among children on PI-based ART. By contrast with the only other study of this combination in children, severe neutropenia was rare. Furthermore, outcomes from this cohort suggest that rifabutin is effective, and a novel option for children who require PI-based ART. Additional study of rifabutin plus PIs in children is urgently needed.
引用
- Rawizza HE, Darin KM, Oladokun R, et al. Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART. J Antimicrob Chemother. 2019. PMID: 31139825. doi:10.1093/jac/dkz219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。